# Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

> **NCT00045110** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 136 (actual)

## Conditions studied

- Adult Anaplastic Astrocytoma
- Adult Anaplastic Oligodendroglioma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Grade I Meningioma
- Adult Grade II Meningioma
- Adult Grade III Meningioma
- Recurrent Adult Brain Tumor

## Interventions

- **DRUG:** erlotinib hydrochloride
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00045110
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2017-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045110, "Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00045110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*